Roth Capital Analysts Decrease Earnings Estimates for CLRB

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Stock analysts at Roth Capital dropped their FY2024 earnings per share (EPS) estimates for Cellectar Biosciences in a research note issued on Monday, November 18th. Roth Capital analyst J. Aschoff now anticipates that the biopharmaceutical company will earn ($1.53) per share for the year, down from their previous forecast of ($1.52). The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($1.57) per share. Roth Capital also issued estimates for Cellectar Biosciences’ Q4 2024 earnings at ($0.32) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at $0.05 EPS, FY2025 earnings at ($0.65) EPS, FY2026 earnings at $0.50 EPS, FY2027 earnings at $1.10 EPS and FY2028 earnings at $1.71 EPS.

Several other analysts have also recently issued reports on the company. Oppenheimer dropped their target price on Cellectar Biosciences from $14.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday. StockNews.com raised Cellectar Biosciences to a “sell” rating in a research report on Thursday, September 26th.

Cellectar Biosciences Trading Up 1.3 %

Shares of NASDAQ CLRB opened at $1.58 on Thursday. The stock has a market capitalization of $65.21 million, a PE ratio of -0.91 and a beta of 1.00. The stock’s fifty day simple moving average is $2.05 and its two-hundred day simple moving average is $2.40. Cellectar Biosciences has a 12-month low of $1.39 and a 12-month high of $4.45.

Cellectar Biosciences (NASDAQ:CLRB) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter.

Institutional Trading of Cellectar Biosciences

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Cellectar Biosciences by 146.7% in the 1st quarter. Vanguard Group Inc. now owns 1,191,081 shares of the biopharmaceutical company’s stock worth $4,741,000 after acquiring an additional 708,191 shares during the last quarter. Rosalind Advisors Inc. raised its stake in Cellectar Biosciences by 335.4% in the 2nd quarter. Rosalind Advisors Inc. now owns 2,705,616 shares of the biopharmaceutical company’s stock worth $6,764,000 after acquiring an additional 2,084,138 shares during the last quarter. AIGH Capital Management LLC raised its stake in Cellectar Biosciences by 8.2% in the 2nd quarter. AIGH Capital Management LLC now owns 3,036,187 shares of the biopharmaceutical company’s stock worth $7,590,000 after acquiring an additional 231,270 shares during the last quarter. XTX Topco Ltd raised its stake in Cellectar Biosciences by 432.4% in the 2nd quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock worth $158,000 after acquiring an additional 51,413 shares during the last quarter. Finally, Sequoia Financial Advisors LLC purchased a new position in Cellectar Biosciences in the 3rd quarter worth $51,000. Institutional investors and hedge funds own 16.41% of the company’s stock.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.